Details

Autor(en) / Beteiligte

• Chitnis, Tanuja
• Foley, John
• Ionete, Carolina
• El Ayoubi, Nabil K.
• Saxena, Shrishti
• Gaitan-Walsh, Patricia
• Lokhande, Hrishikesh
• Paul, Anu
• Saleh, Fermisk
• Weiner, Howard
• Qureshi, Ferhan
• Becich, Michael J.
• da Costa, Fatima Rubio
• Gehman, Victor M.
• Zhang, Fujun
• Keshavan, Anisha
• Jalaleddini, Kian
• Ghoreyshi, Ati
• Khoury, Samia J.

Titel

Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis

Ist Teil von

• Clinical immunology (Orlando, Fla.), 2023-08, Vol.253, p.109688-109688, Article 109688

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2023

Link zum Volltext

Quelle

ScienceDirect

Beschreibungen/Notizen

• An 18-protein multiple sclerosis (MS) disease activity (DA) test was validated based on associations between algorithm scores and clinical/radiographic assessments (N = 614 serum samples; Train [n = 426; algorithm development] and Test [n = 188; evaluation] subsets). The multi-protein model was trained based on presence/absence of gadolinium-positive (Gd+) lesions and was also strongly associated with new/enlarging T2 lesions, and active versus stable disease (composite of radiographic and clinical evidence of DA) with improved performance (p < 0.05) compared to the neurofilament light single protein model. The odds of having ≥1 Gd+ lesions with a moderate/high DA score were 4.49 times that of a low DA score, and the odds of having ≥2 Gd+ lesions with a high DA score were 20.99 times that of a low/moderate DA score. The MSDA Test was clinically validated with improved performance compared to the top-performing single-protein model and can serve as a quantitative tool to enhance the care of MS patients.